EntryPoint Capital’s Xeris Biopharma Holdings XERS Stock Holding History

EntryPoint Capital’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$640K	Sell	80,750 -15,460	-16%	-$98.7K	0.16%	226
2026 Q1	$558K	Buy	96,210 +28,127	+41%	+$186K	0.16%	209
2025 Q4	$534K	Buy	68,083 +15,068	+28%	+$119K	0.21%	141
2025 Q3	$432K	Sell	53,015 -19,884	-27%	-$132K	0.17%	222
2025 Q2	$340K	Sell	72,899 -2,807	-4%	-$12.9K	0.17%	227
2025 Q1	$416K	Buy	75,706 +22,946	+43%	+$92.6K	0.19%	173
2024 Q4	$179K	Buy	52,760 +18,127	+52%	+$58.3K	0.08%	610
2024 Q3	$98.7K	Sell	34,633 -11,790	-25%	-$30.3K	0.06%	557
2024 Q2	$104K	Buy	46,423 +42,460	+1,071%	+$85.6K	0.05%	795
2024 Q1	$8.76K	Buy	+3,963	New	+$10.3K	0.01%	1256

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

EntryPoint Capital's XERS Position: Q2 2026 in Review

EntryPoint Capital reduced its Xeris Biopharma Holdings (XERS) stake by 16% in Q2 2026, selling an estimated $98.7K and leaving 80,750 shares worth $640K. The position accounts for 0.16% of the portfolio, ranked #226.

EntryPoint Capital first reported a position in XERS in Q1 2024 and has held it in 10 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

EntryPoint Capital held 80,750 shares of Xeris Biopharma Holdings worth $640K as of Q2 2026.
EntryPoint Capital sold 15,460 Xeris Biopharma Holdings shares in Q2 2026, an estimated $98.7K.
Xeris Biopharma Holdings made up 0.16% of EntryPoint Capital's portfolio in Q2 2026, its #226 holding.
EntryPoint Capital first reported a position in Xeris Biopharma Holdings in Q1 2024 and has held it in 10 quarters since.
241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.